Bright Minds Biosciences Announces Positive Phase 1 Data from Study of its BMB-101 Lead Compound

August 8, 2023

(24/7 MARKET NEWS) – Bright Minds Biosciences Inc. (NASDAQ:DRUG) reported, this morning, positive results of the qEEG (Quantitative Electroencephalogram) data in Cohort 4 of its first-in-human Phase 1 study of its lead compound, BMB-101, following its July 20, 2023 completion of the study announcement, along with positive topline data that demonstrated BMB-101’s excellent safety and tolerability profile in the single ascending dose, multiple ascending dose and food effects parts of the study. BMB-101 also demonstrated central target engagement and predictable plasma pharmacokinetics.

Bright Minds Biosciences is trading at $3.70, up $0.48 (+14.90%), on 317 premarket shares traded.

Its 52-week range is $2.013 to $23.75. Its next key inflection point is $4.60 and if it can break through on strong trading volume, it’s likely that it challenges its October and September trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.